Calamos Advisors’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$93.5M Buy
777,663
+57,857
+8% +$6.68M 0.33% 59
2025
Q4
$75.8M Buy
719,806
+209,606
+41% +$19.7M 0.28% 77
2025
Q3
$42.8M Sell
510,200
-13
-0% -$1.07K 0.16% 140
2025
Q2
$40.4M Sell
510,213
-158,002
-24% -$12.6M 0.16% 145
2025
Q1
$60M Sell
668,215
-184,632
-22% -$17.2M 0.26% 85
2024
Q4
$84.8M Sell
852,847
-100,857
-11% -$10.4M 0.35% 53
2024
Q3
$108M Buy
953,704
+19,291
+2% +$2.29M 0.47% 31
2024
Q2
$116M Sell
934,413
-63,036
-6% -$8.12M 0.51% 26
2024
Q1
$132M Buy
997,449
+56,176
+6% +$6.92M 0.62% 19
2023
Q4
$103M Sell
941,273
-29,334
-3% -$3.04M 0.5% 27
2023
Q3
$99.9M Buy
970,607
+188,466
+24% +$20.3M 0.52% 29
2023
Q2
$90.3M Buy
782,141
+68,896
+10% +$7.82M 0.45% 34
2023
Q1
$75.9M Sell
713,245
-60,622
-8% -$6.55M 0.37% 53
2022
Q4
$85.9M Sell
773,867
-37,721
-5% -$3.86M 0.4% 47
2022
Q3
$69.9M Buy
811,588
+162,388
+25% +$14.5M 0.32% 62
2022
Q2
$59.2M Buy
649,200
+17,920
+3% +$1.59M 0.26% 92
2022
Q1
$51.8M Sell
631,280
-167,898
-21% -$13.2M 0.19% 125
2021
Q4
$61.2M Sell
799,178
-10,590
-1% -$843K 0.23% 103
2021
Q3
$60.8M Buy
809,768
+50,329
+7% +$3.83M 0.27% 92
2021
Q2
$59.1M Buy
759,439
+84,336
+12% +$6.27M 0.27% 84
2021
Q1
$49.7M Buy
675,103
+12,627
+2% +$931K 0.27% 84
2020
Q4
$51.7M Sell
662,476
-17,831
-3% -$1.36M 0.3% 83
2020
Q3
$53.8M Sell
680,307
-38,023
-5% -$2.98M 0.35% 64
2020
Q2
$53M Sell
718,330
-99,893
-12% -$7.52M 0.37% 61
2020
Q1
$60.1M Sell
818,223
-401,487
-33% -$31.6M 0.47% 41
2019
Q4
$106M Sell
1,219,710
-8,663
-0.7% -$712K 0.52% 35
2019
Q3
$98.7M Buy
1,228,373
+44,902
+4% +$3.6M 0.54% 36
2019
Q2
$94.7M Buy
1,183,471
+117,949
+11% +$9.03M 0.53% 35
2019
Q1
$84.6M Buy
1,065,522
+100,156
+10% +$7.49M 0.53% 41
2018
Q4
$70.4M Buy
965,366
+66,770
+7% +$4.71M 0.46% 51
2018
Q3
$60.8M Sell
898,596
-9,908
-1% -$631K 0.33% 77
2018
Q2
$52.6M Sell
908,504
-25,937
-3% -$1.46M 0.32% 86
2018
Q1
$48.6M Sell
934,441
-64,220
-6% -$3.47M 0.32% 89
2017
Q4
$53.6M Sell
998,661
-208,423
-17% -$11.6M 0.27% 69
2017
Q3
$73.8M Sell
1,207,084
-112,558
-9% -$6.82M 0.57% 32
2017
Q2
$80.7M Buy
1,319,642
+1,441
+0.1% +$87.7K 0.6% 35
2017
Q1
$79.9M Sell
1,318,201
-13,391
-1% -$812K 0.63% 31
2016
Q4
$74.8M Sell
1,331,592
-14,318
-1% -$838K 0.59% 39
2016
Q3
$80.2M Sell
1,345,910
-11,304
-0.8% -$661K 0.57% 37
2016
Q2
$74.6M Sell
1,357,214
-367,520
-21% -$19.6M 0.52% 45
2016
Q1
$87.1M Buy
1,724,734
+25,367
+1% +$1.24M 0.58% 34
2015
Q4
$85.6M Sell
1,699,367
-83,795
-5% -$4.22M 0.54% 40
2015
Q3
$84M Buy
1,783,162
+37,023
+2% +$1.97M 0.58% 38
2015
Q2
$94.9M Buy
1,746,139
+595,356
+52% +$33.4M 0.59% 36
2015
Q1
$63.1M Sell
1,150,783
-20,210
-2% -$1.14M 0.4% 73
2014
Q4
$63.5M Sell
1,170,993
-8,000
-0.7% -$446K 0.42% 67
2014
Q3
$66.7M Sell
1,178,993
-436
-0% -$24.5K 0.45% 61
2014
Q2
$65.1M Buy
1,179,429
+26,679
+2% +$1.46M 0.41% 66
2014
Q1
$62.4M Sell
1,152,750
-2,612
-0.2% -$135K 0.4% 68
2013
Q4
$55.2M Sell
1,155,362
-805,510
-41% -$36.8M 0.35% 75
2013
Q3
$89.1M Sell
1,960,872
-83,657
-4% -$3.82M 0.56% 46
2013
Q2
$90.6M Buy
+2,044,529
New +$91.3M 0.59% 42

Other funds holding MRK

Calamos Advisors's MRK Position: Q1 2026 in Review

Calamos Advisors increased its Merck (MRK) stake by 8% in Q1 2026, buying an estimated $6.68M and bringing the position to 777,663 shares worth $93.5M. The position accounts for 0.33% of the portfolio, ranked #59.

Calamos Advisors first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $132M in Q1 2024. 3,777 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Calamos Advisors held 777,663 shares of Merck worth $93.5M as of Q1 2026.
  • Calamos Advisors bought 57,857 Merck shares in Q1 2026, an estimated $6.68M.
  • Merck made up 0.33% of Calamos Advisors's portfolio in Q1 2026, its #59 holding.
  • Calamos Advisors first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • Calamos Advisors's Merck position peaked at $132M in Q1 2024.
  • 3,777 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Calamos Advisors's 13F filing for Q1 2026, filed 4 May 2026.